Fri, Aug 1, 2014, 8:43 PM EDT - U.S. Markets closed

Recent

% | $
Click the to save as a favorite.

Hemispherx Biopharma, Inc. Message Board

deepdeepdeepthroat 165 posts  |  Last Activity: Jul 31, 2014 6:56 AM Member since: Nov 22, 2002
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • deepdeepdeepthroat deepdeepdeepthroat Jul 31, 2014 6:56 AM Flag

    The fact that the pumpers have moved on to preposterous ebola pumping tells you that they realize that their bogus BARDA pumps had no credibility.

  • Reply to

    Picked up more yesterday

    by buddystovall Jul 30, 2014 2:58 PM
    deepdeepdeepthroat deepdeepdeepthroat Jul 30, 2014 6:29 PM Flag

    Are the people pumping Ebola capable of feeling embarrassed or ashamed?

    There is not even a mouse study for using an HEB product for Ebola. This pump is built on nothing more than an idle Carter daydream from more than a decade ago.

  • Reply to

    The News

    by krav_nick Jul 25, 2014 7:37 AM
    deepdeepdeepthroat deepdeepdeepthroat Jul 25, 2014 2:17 PM Flag

    "boneynj • 19 minutes ago Flag

    Bump up! to the top!"

    Lol

  • The UAB study data so far presented did not include a Flumist only arm, and so far shows only that increasing the dose of Ampligen decreases the immunogenicity of Flumist.

    In today's press release they try to compare these results with a 2000 study that used one dose of Flumist, while the UAB study subjects were given three doses of Flumist.

    Also, I don't see where on the UAB poster that HEB specified exactly what assay they used in their IgA measurements, which makes it harder to compare with the 2000 data.

    Until we see Flumist+Ampligen directly compared with Flumist-Alone with the same number of doses given over the same amount of time during the same influenza seasons in the same patient population with the same assays, we really can't say whether or not Ampligen helps or hurts Flumist.

  • deepdeepdeepthroat deepdeepdeepthroat Jul 25, 2014 1:38 PM Flag

    hebmaster's other refuge is to retreat into his complete ignorance of immunology.

  • deepdeepdeepthroat deepdeepdeepthroat Jul 25, 2014 1:24 PM Flag

    hebmaster's only solace from the grim truth about HEB is to retreat into his misinterpretations of old PowerPoint slides that a presenter has not got around to updating.

  • deepdeepdeepthroat deepdeepdeepthroat Jul 25, 2014 1:14 PM Flag

    This should also negate bones' mindless "bump" posts.

  • deepdeepdeepthroat deepdeepdeepthroat Jul 25, 2014 1:06 PM Flag

    The 2012 NDA was obviously doomed all along.

    Only those who fell for HEB's misleading FDASIA pumps thought that there was any chance.

    I wish those poor souls good luck in Judge Yohn's federal courtroom.

  • deepdeepdeepthroat by deepdeepdeepthroat Jul 25, 2014 12:59 PM Flag

    ""The safety assessment of Ampligen revealed a number of discrepancies in the sponsor’s data. Key issues include some serious adverse events not counted by the sponsor, marked laboratory abnormalities that were not reported in the database, miscoding of adverse events and reasons for discontinuation, lack of adverse event definitions, and misleading or incomplete presentations of data. These discrepancies raise significant questions about data from all of the trials and whether or not the data are sufficient to determine the safety profile of Ampligen."

  • deepdeepdeepthroat by deepdeepdeepthroat Jul 11, 2014 7:40 AM Flag

    johnnyd_79902 • Jan 21, 2014 12:30 PM Flag

    One official result to look for is BARDA. HEB filed two Stage 1 white papers. Assuming the submission deadline they met was January 30 - we should hear whether we've moved to Stage 2 by the end of April. Stage 2 does not necessarily mean funding but it means BARDA is _very_ interested. But IMO, since we've got _exactly_ what they are looking for. A move to stage 2 means funding and it will be a very big deal.

    tick tock..

  • Reply to

    Barda....

    by hebmasterll Jul 11, 2014 6:58 AM
    deepdeepdeepthroat deepdeepdeepthroat Jul 11, 2014 7:02 AM Flag

    Prediction: We will not see any press releases about barda.

    Prediction: hebmaster will continue to hallucinate about barda grants.

  • Reply to

    Bonus Time

    by deepdeepdeepthroat Jul 10, 2014 8:41 PM
    deepdeepdeepthroat deepdeepdeepthroat Jul 11, 2014 6:43 AM Flag

    "An Outrageous, Shameless Act by Hemispherx's Board of Directors" -Adam Feuerstein

    " but for once I dont disagree with adam "
    -hebmasterll • 17 minutes ago

  • Reply to

    Bonus Time

    by deepdeepdeepthroat Jul 10, 2014 8:41 PM
    deepdeepdeepthroat deepdeepdeepthroat Jul 11, 2014 6:25 AM Flag

    "Chief executive officer Bill Carter was awarded a five percent bonus totaling $1.1 million "

    "Not a bonus.... but for once I dont disagree with adam "

    Take your meds, mike.

  • Reply to

    Bonus Time

    by deepdeepdeepthroat Jul 10, 2014 8:41 PM
    deepdeepdeepthroat deepdeepdeepthroat Jul 11, 2014 6:21 AM Flag

    "An Outrageous, Shameless Act by Hemispherx's Board of Directors

    BY Adam Feuerstein Follow | 05/01/13 - 12:03 PM EDT

    PHILADELPHIA (TheStreet) -- Hemispherx Biopharma's (HEB_) board of directors committed the most egregious act of shareholder fleecing I've ever come across. My mouth is agape, in bewilderment, as I type this:

    Chief executive officer Bill Carter was awarded a five percent bonus totaling $1.1 million based on the net proceeds resulting from Hemispherx's sale of 30 million shares of company stock through an At-The-Market (ATM) financing arrangement last fall.

    Hemispherx's board concluded the sale of company stock on the open market -- something publicly traded companies do routinely -- actually represented a sale of "company assets not in the ordinary course of its business." Under this definition, Carter was contractually eligible to receive five percent of the proceeds.

    The sale of 30 million shares of Hemispherx stock during the fourth quarter 2012 netted $23 million for the company. Of that, Hemispherx's directors wrote a check to Carter for $1.1 million.

    Thomas Equels, Hemispherx's vice chairman and lawyer, also received the same $1.1 million "ATM bonus" under his employment contract. The bonuses and the reasons for granting them were disclosed in Hemispherx's most recent 10-K filed with the SEC.

    So, 10 percent of the cash raised by Hemispherx late last year didn't flow into the company's coffers, but ended up instead in the personal bank accounts of two of its top executives. And this was all legal because Hemispherx's board of directors voted for it.

    Hemispherx was selling those 30 million shares under the subterfuge of its ATM agreement which allows the company to disclose sales only when it files quarterly reports to the SEC. And of course, at that same time, Hemispherx shares were losing 80 percent of their value after the FDA and an independent advisory panel sharply criticized the company for the way it conducted clinical tria

  • Reply to

    Bonus Time

    by deepdeepdeepthroat Jul 10, 2014 8:41 PM
    deepdeepdeepthroat deepdeepdeepthroat Jul 11, 2014 6:08 AM Flag

    Sadly, there is nothing usual about the scamsters who run HEB taking extra cash bonuses.

    Remember when they rewarded themselves with milllion dollar bonusesas a reward for their megadilution last year?

  • deepdeepdeepthroat by deepdeepdeepthroat Jul 10, 2014 8:41 PM Flag

    HEB insiders are not content with only end-of-year cash bonuses. No! No! No! They also need mid year cash bonuses.

    This is why HEB needs to dump shares at the market to raise cash:

    "On July 8, 2014, the Board of Directors (the “Board”) of Hemispherx Biopharma, Inc. (the “Company”) approved the granting, at the recommendation of the Compensation Committee (the “Committee”), of mid-year performance bonuses to the Senior Management team.

    The Committee in light of pre-established individual and Company-wide goals and objectives evaluated the performance of each key executive in order to determine respective annual incentive opportunities considering base salary and fees, short and long-term incentive opportunity and any special/supplemental benefits or payments. Based upon all of the foregoing, the Committee determined that the following Performance Bonuses should be granted in 2014 to the following NEO, along with others:

    1. At the rate of 25% of their respective 2014 year-end base compensation:

    i. Dr. William Carter (Chairman, CEO, President & Chief Scientific Officer) for $250,691;
    ii. Thomas Equels (Vice Chairman, CFO, Secretary & General Counsel) for $134,203;
    iii. Wayne Springate (SVP of Operations) for $50,181;
    iv. Dr. David Strayer (Medical Director and Chief Medical Officer) for $67,369; and
    v. Adam Pascale (Chief Accounting Office and Controller) for $33,459."

  • Reply to

    Has anybody heard about approval yet?

    by hebmasterlll Jun 29, 2014 1:09 PM
    deepdeepdeepthroat deepdeepdeepthroat Jun 29, 2014 3:32 PM Flag

    Does Peter call Mike a loser?

  • deepdeepdeepthroat deepdeepdeepthroat Jun 27, 2014 4:21 PM Flag

    In case you haven't heard of Stratton-Oakmont, watch "Wolf of Wall Street."

  • Reply to

    Thank You Brady Bunch

    by vizsla1225 Jun 4, 2014 4:08 PM
    deepdeepdeepthroat deepdeepdeepthroat Jun 27, 2014 4:12 PM Flag

    Sadly, it is defective reasoning such as this that led mike's life into a dead end in his brother's basement.

  • Reply to

    Thank You Brady Bunch

    by vizsla1225 Jun 4, 2014 4:08 PM
    deepdeepdeepthroat deepdeepdeepthroat Jun 27, 2014 4:07 PM Flag

    Lol

    In addition to his hedge fund delusions, his delusions that I use more than one ID, he has now acquired delusions that I have children.

    It must be very boring for hebmaster living in his brother's basement for him to spend so much time wallowing in his delusions and creating his fantasy worlds.

HEB
0.285+0.005(+1.79%)Aug 1 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.